Sanofi-Aventis pharmaceutical

The search for an effective non-peptide oxytocin antagonist has become a major goal of a number of pharmaceutical companies because of the poor pharmacokinetic properties and especially the lack of oral bioavailability associated with peptidic antagonists. Early research in this field was dominated by Merck, but in recent years significant research efforts at GlaxoSmithKline and Serono have been published. A number of other companies, notably Sanofi-Aventis, Yamanouchi and Wyeth, have had a major presence in vasopressin receptor research and oxytocin is frequently included in patent claims for the molecules. Occasionally, oxytocin-selective compounds have been reported, usually derived by adaptation of the vasopressin antagonist template. 

Ramipril (5, HOE-498), discovered at Hoechst (now Sanofi-Aventis), was launched in the United States as Altace in 1991 and is currently marketed by King Pharmaceuticals. Upon administration, rapid hepatic cleavage of the ethyl ester results in ramiprilat (42), the... 

Several companies including Merck,23,24 Sanofi-Aventis,26,27 and Proctor Gamble,28 published papers that described research programs that targeted selective Kvl.5 blockers. In 2003 Cardiome Pharmaceuticals submitted the first of several patents applications that describe tra s-cyclohexylamine alkyl ethers (including 8, 9, and 1) and claimed that these compounds showed specificity for inhibition of atrially expressed potassium... 

New contacts with another pharmaceutical group (Sanofi Aventis). 

Research Triangle Institute Rodaris Pharmaceuticals Limited Roche Palo Alto LLC Sanofi-Aventis Deutschland GmbH SB Corporation... 

In 2003, Vial and co-workers established a collaboration with the pharmaceutical company Sanofi Aventis and its highly motivated teams led by J. P. Maffrand and L. Fraise to ensure the clinical development of their prize compound in humans, a task beyond the scope of their academic expertise. 

Kenneth L. Hastings, DrPH, DABT, Associate Vice-President for Regulatory Policy, Sanofi-Aventis, 4520 East West Highway, Suite 210, Bethesda, MD 20814, E-mail kenneth.hastings sanofi-aventis.com Chapter 1 Current Regulatory Expectations for Immunotoxicology Evaluation of Pharmaceuticals... 

Michael J. Bowker studied chemistry and received his doctorate in Organic Chemistry from the University of Leeds, UK. After 5 years working for a multinational polymer company, he moved to May Baker Ltd., a UK subsidiary of Rhone-Poulenc Santd (now Sanofi-Aventis). He was a Director of Analytical Chemistry for about 15 years and, more recently. Director of Preformulation at Aventis Pharma Ltd. He has been intimately involved in preformulation and solid-state activities, on a worldwide basis for more than 15 years. He has published several research papers and one chapter for a book on pharmaceutical salts and is currently a Director of M. J. Bowker Consulting Limited, a small company undertaking consultancy in salt selection, polymorph selection and pharmaceutical preformulation. 

Investors appeared less convinced than the French government about the long-term prospects of the merger and were unhappy that the outcome of the merger was dictated by politics more than finance. However, the PharmaFrance 2004 report on the state of the French pharmaceutical industry suggested that Sanofi-Aventis would represent a resurgence of France s pharmaceutical sector as it takes up its position as the third largest pharmaceutical company in the world (57). 

---